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Abstract
Background: Drug resistance has now posed more severe and emergent threats to human health and infectious
disease treatment. However, wet-lab approaches alone to counter drug resistance have so far still achieved limited
success due to less knowledge about the underlying mechanisms of drug resistance. Our approach apply a
heuristic search algorithm in order to extract active network under drug treatment and use a random walk model
to identify potential co-targets for effective antibacterial drugs.
Results: We use interactome network of Mycobacterium tuberculosis and gene expression data which are treated
with two kinds of antibiotic, Isoniazid and Ethionamide as our test data. Our analysis shows that the active drug-
treated networks are associated with the trigger of fatty acid metabolism and synthesis and nicotinamide adenine
dinucleotide (NADH)-related processes and those results are consistent with the recent experimental findings. Efflux
pumps processes appear to be the major mechanisms of resistance but SOS response is significantly up-regulation
under Isoniazid treatment. We also successfully identify the potential co-targets with literature confirmed evidences
which are related to the glycine-rich membrane, adenosine triphosphate energy and cell wall processes.
Conclusions: With gene expression and interactome data supported, our study points out possible pathways
leading to the emergence of drug resistance under drug treatment. We develop a computational workflow for
giving new insights to bacterial drug resistance which can be gained by a systematic and global analysis of the
bacterial regulation network. Our study also discovers the potential co-targets with good properties in biological
and graph theory aspects to overcome the problem of drug resistance.
Background
Drug resistance has been posing an emergent threat to
human health and infectious disease treatment. Drug
resistance is a natural survival mechanism for bacteria
when the cell is exposed to drug exposure. Mycobacter-
ium tuberculosis (Mtb) remained to be one of the lead-
ing and widely spread killer infectious diseases. In 2008,
estimated 390000-510000 cases of multidrug resistant
Mtb recorded in WHO 2010 and this problem is wor-
sened significantly by the emergence of drug resistance
under clinical drug used. Up to now, methods employed
to tackle the problem of drug resistance are rather arbi-
trary. Several wet-lab experiments and clinical decisions
like rotation of antibiotic combinations, identification of
new targets and chemical entities that may be less muta-
ble are being explored to counter this problem by inhi-
biting the resistance mechanism [1]. However, those
strategies are still not effective enough and have so far
achieved limited success due to limited knowledge about
how the resistance mechanisms are triggered in bacteria
upon antibiotic drug treatment [2].
The gene expression depended upon the mechanism of
action of the drug in the cell as a consequence of the
action through metabolic and regulatory adjustments or
triggering drug resistance more explicitly [3]. The high-
throughput of microarray technology has led to explosion
of data concerning the expression levels of the genes but
most of statistical methods such as fold change and t-test
identify genes with significant changes. However, based
solely on the patterns of variations in terms of the increase
or decrease in the expression levels of individual genes, it
is in general hard to know the related processes involved
in the mechanisms of the drug response and resistance.
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any medium, provided the original work is properly cited.Due to the increasing availability of protein interaction
networks, network-based analysis provides an opportu-
nity to discover an active (significant) network. The net-
work provides a systems-level view of how genes and
their products interact within the cell and explain the
biological actions under specific condition. However,
one weakness of the protein-protein interaction data is
that it contains no information about the conditions
under which the interactions may take place which
means it is not a real snapshot of the interactions in
vivo, but a union of the interactions activated under var-
ious conditions. Except protein interaction network sup-
ported, the network will be much more biologically
insightful if the expression data is incorporated with
them. Recently some various network-based approaches
[4-8] based on protein interaction networks have
obtained much better performance than traditional sta-
tistical approaches only based on the gene expression
values. They first applied a scoring scheme to evaluate
an active level of the network based on the gene expres-
sion of each gene or its interactions. In the second step,
a search procedure is implemented to find the node
connected in a sub-network has a highest score and to
form a maximum-scoring sub-network. Due to this kind
of the problem is NP-hard, several heuristic or approxi-
mate methods such as simulated annealing, locally
greedy search and mathematical programming methods
were proposed. Ideker et al. first formulated the pro-
blem of the active pathway detection, where the scoring
function is given by a summation function of all genes’
differentially expressed p-value within the sub-networks
[9]. Dittrich et al. used an additive function of p-values
based on a mixture model [10]. Breitling et al. proposed
a method to score active sub-networks in terms of
genes’ order of their differential expression significance
[11]. Sohler et al. searched for active networks by span-
ning the networks with a given set of seed proteins [7].
Such approaches as the vertex-based methods usually
do not further select the active interaction relationships
among the identified proteins. However, taking all the
interactions among those ‘active’ proteins detected by
those methods is inadequate, because under a particular
condition, only a part of the interactions may be active.
Guo et al. proposed a novel edge-based scoring to
extract an active sub-network related to some investi-
gated gene expression profiles under specific condition
[12]. Han et al. calculated the average Pearson correla-
tion coefficients between the hubs and their neighbors
in the protein interaction networks [13]. Zhao proposed
an integer linear programming (ILP) model to find the
signal pathways by utilizing both protein interactions
and microarray data [14]. Some edge-based scoring
methods use statistical measures such as Pearson corre-
lation coefficient for analyzing the pair relationships
which do not work well in the small set of the microar-
r a yd a t aa n dc o u l db ea l s ou n s u i t a b l et oe x p l o r et r u e
relationships because they are overly sensitive to the
expression values.
With the availability of high throughput microarray
data and interactome network, it is feasible to address
the issue of drug resistance from the system’sp e r s p e c -
tive. Wu et al. integrated those two kinds of the informa-
tion to present a novel network-based approach to
identify effective combination of drugs by comparing the
sub-network affected by individual drugs [15]. Typically,
the target of a drug inhibits the pathogen or arrests its
growth but the resistant machinery is established via cer-
tain pathways. A recent idea is to counter the drug resis-
tance that called a “co-target” instead of being the
ancillary or secondary targets that have a critical physio-
logical function for the survival of a cell and it helps a
primary drug to inhibit the resistance mechanism [2].
Thus, a co-target could be either essential or non-essen-
tial but it is necessary to have a strong influence in the
resistance network. Raman and Chandra formulated the
problem of identifying a co-target as a search for the
shortest paths obtained from the bacteria protein inter-
action network and calculated the “betweenness” attri-
bute of genes to identify the potential co-target based on
t h eg e n ee x p r e s s i o nv a l u e s[ 2 ] .A l t h o u g ht h es h o r t e s t
path analysis may yield a higher coverage than observed
directly neighbors locally from the protein interaction
data, this approach considers only a single length which
ignores the potential contribution of the other paths
with longer length. Due to the small world property of
biological network, the shortest path length in a biologi-
cal network is typically very small and most of the time
there will be additional “relatedness” between two gene
nodes [16,17]. However, the shortest paths are the only
routes of drug resistance and there are some “back-up”
ways to make the robustness of the mechanism in bac-
teria [18]. Without any essential pathways related to the
mechanism of drug resistance, Ayati et al. applied
balanced network bipartition method to discover the co-
targets which separate interaction network into discon-
nected pieces to effectively disrupt the survival of a bac-
terium when it has multiple pathways to trigger the drug
resistance [18]. However, all of them simply take all the
interactions in the public database as the edges and did
not take the active interactions under antibiotic drug
treatment into consideration.
We apply a computational approach that uses both
gene expression data and interactome network to iden-
tify the active networks under antibiotic drug treatment.
Then, we apply a random walk model to discover co-
targets that are highly likely to affect the genes related
to the mechanisms of the drug resistance through the
main and back-up paths.
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The overall workflow of our methods consists six steps
which is shown in Figure 1. We use interactome net-
work from STRING database in step 1 and assign
weight values to the interactions based on the confi-
dence scores and gene expression values from antibiotic
drug treatment and control samples in step 2. We pre-
sent an A* heuristic search method to identify the active
networks under antibiotic drug treatment in step 3 and
then classify different functional drug resistance path-
ways using known annotated curated resistance proteins
[19] in step 4. We apply random walk method to dis-
cover potential co-targets in step 5 and 6.
Network construction from microarray data and protein-
protein interactions database
The microarray data implies gene expression either up-
regulated or down-regulated can be revealed in terms of
two colored channel in the microarray data representing
the intensity of the antibiotic treatment and control
samples. The gene expression ratios are calculated as
the median value of the pixels minus background pixel
median value for one color channel divided by those for
the other channel. We extract the median value of the
log base 2 of each gene in experimental dataset because
the median value of the normalized ratio is much harder
to be affected by noise than the mean value. We derive
a genome-scale interactome network from STRING
database http://string-db.org/ where the interactions
extracted from published literature including experimen-
tally studied interactions from genome analysis [20]. The
latter is based on well established bioinformatics con-
cepts and methods including structural and functional
linkages, genes belonging to a single operon or common
neighborhood, pairs of proteins which share metabolites
between them and suggested associations based on co-
expression, domain fusion or conserved in a number of
species [20]. In STRING database, a continuous confi-
dence score is assigned to each interaction which is
derived by benchmarking the performance of the predic-
tions against a common reference set of trusted and true
associations [20]. A higher confidence score Cuv is
assigned while an interaction between two proteins u
and v is supported by more types of evidences.
We formulate an undirected interactome network
defined as G(V, E) where the node set V represents pro-
tein which is the product of gene v (vÎV) and edge set
E represents the interactions e (eÎE) in the network.
Because the network contains some false positives, we
use the absolute value of the expression profile of each
gene and the larger value denotes more significant dif-
ferential expressed genes under drug treatment. We
apply the weight to each edge which is defined in Equa-
tion (1) as the product of the confidence score Cuv and
the sum of the absolute value of gene expression values
between two corresponding genes u and v in the edge.
w(e)=w(u,v) = A(u,v)
= Cuv ×
    Expu
    +
   Expv
     (1)
Expu and Expv are the average of the gene expression
values of node u and v in the microarray. The higher
the expression of the Expu or Expv denotes the larger
differential expression changes of the genes. Then, we
use the adjacent matrices A = (auv)n*n to represent inter-
actome network among n nodes where auv denotes the
weights of interactions between nodes u and v.
A* algorithm as heuristic search
In order to study the active networks relevant to drug
response and resistance, it is required to define the
source nodes to understand the flow of drug actions.
DrugBank database http://www.drugbank.ca/ provides
drug-related information and also determines the drug
targets of an antibiotic drug [21]. Previous studies
showed that the metabolic adjustments often occur so
as to minimize the effect of inhibition on the particular
protein and denoted that multiple proteins in the drug-
related functional mechanism may be also targeted
[22,23]. According to the effect of such adjustments, it
is reasonable to consider thep r o t e i n si n v o l v e di nt h e
whole pathway as the source nodes rather than an indi-
vidual protein [2]. Therefore, we use the drug targets
from DrugBank database and the genes associated with
the drug-related function as the source nodes for
searching active networks.
In the protein interaction network, we try to search
the linear or tree type active pathways and then assem-
ble those paths to form the sub-network. However,
searching linear paths may expand a large collection of
Figure 1 The overall workflow of our method.
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In order to determine the range of path lengths in the
network we would detect, we apply the heap-based Dijk-
stra’s algorithm for each node to get the maximum
length of the shortest path of all pairs of nodes in the
network [24]. This information shows if any pair of
nodes in the network can link to others at most the
l e n g t ha n dw et h u su s et h el e n g t ho ft h el o n g e s ts h o r t -
est path as the maximum length in the path searching.
Therefore, we assume that the active network extraction
issue is a minimum score linear path searching problem
with the fixed length [25]. First, we normalize the
weight w(e)o ft h ee d g ee calculated by Equation (1) to
be the range [0-1]. Then, we transfer the larger weight
o ft h ee d g et ob eas m a l l e rs c o r ea n dt h es c o r eo ft h e
edge e between two corresponding genes u and v is cal-
culated as score(e)=s c o r e ( u, v)=- l o g ( w ( u,v)). The
negative logarithm makes larger weight become smaller
score and so on. We define the score of a path as the
sum of scores of edges in the path and the formula is
defined in Equation (2):
score(p)=
 
e∈p
score(e) (2)
Where score(e) is the score of an edge e in the path p.
To speed up the procedure in search of the minimum
s c o r el i n e a rp a t h ,i tn e e d st op r u n et h eu n e x p l o r e dn e w
nodes heuristically. We use the idea of A* search to
design a pruning strategy and the heuristic function is
to determine the weight of a pathway that reflects signif-
icance to some extent. We first run the search proce-
dure 5000 times to determine the scores of all paths in
the experiments formed a normal distribution. And
then, the error rate based on the standard deviation
scorestd, minimum score as scoremin and an average
score of edges as scoreavg in the distribution help us to
find the optimal pathway in estimating a bound heuris-
tic function h(x)f o ran o d ex.W ee m p l o ya nA *s e a r c h
method that can explore heuristically after searching a
fix length d in the paths and calculate the weight of a
path form root node to the current node x as function g
(x). The overall heuristic function of f(x) is defined in
Equation (3) for finding a pathway with an optimal
(minimum) score.
f (x) = g(x) + h(x)
= score(Pd) + scoremin × (l − d)
(3)
where l means the length of a path, d means the
l e n g t hf r o mt h es o u r c en o d et h a tw eh a v ea l r e a d yt r a -
versed in the network, score(Pd) means the sum of the
s c o r eu pt ot h ec u r r e n tn o d ex with a length parameter
d,s c o r e min means the minimum edge score in the
network.
Because the lower f(x) a node is estimated, the more
likely is it to be searched first. We set a bound score for
ap a t hp with length l that is defined as Equation (4) to
control the quality of the path we could find:
Bound(p)=
 
scoreavg − α × scorestd
 
× l (4)
a is a constant factor to control the bound, scoreavg
and scorestd means the average score and the standard
deviation.
While we move to the next node through the edge in
each search process, we compute heuristic function f(x)
and compare it with the initially-set bound score. If f(x)
exceeds the initially-set bound score, we do not expand
the node further. For the nodes that are allowed to
expand, their children nodes are expanded and their
heuristic functions are computed and compared with
the bound score again until the search reaches the end
node. As the example in Figure 2, we consider finding a
pathway with length l = 7 from the initial node A to the
end node H. First we explore a fix length d = 2 from
initial node A that lead us to node C, we start to esti-
mate the score of a path with an additional length of 5
that yields a total weight 11 from current node C. The
estimated score of the path is smaller than the bound
score 11.13, therefore, we continue to traverse its chil-
dren. The function of f(x) of current node D is 13.2 and
therefore we cannot search into its children. We apply
heuristic method to prune the search space instead of
exhaustively searching for all the edges in the network.
The known drug resistance genes reported in the pre-
vious research further help in classification of the paths
[19]. After searching the paths using our heuristic
method, we identify the potential drug resistance path-
ways with at least one curated resistance protein within
Figure 2 An example for A* searching method.
Chen et al. BMC Systems Biology 2012, 6:5
http://www.biomedcentral.com/1752-0509/6/5
Page 4 of 14the paths and assemble them into the active resistance
network with active drug resistance gene set GDR.
Random walk to discover co-target
Random walk (RW) is a ranking algorithm which simu-
lates a random walker starts on a set of seed nodes and
moves to its immediate neighbors randomly at each step
[26]. Each node in the graph is ranked by its probability
of the random walker reaching the other nodes and the
procedure of the RW model provides the basic idea to
estimate the influence from the drug target to the other
genes in the weighted network.
Initial probability for primary drug treatment using RW
Based on the characteristic of RW, we apply it to dis-
cover potential co-targets that have the maximum prob-
ability to affect the genes related to the drug resistance
mechanisms. First, for every node v (vÎV), we define adj
(v) which describes the set of nodes u with direct inter-
action with node v in the network G, and ws(v)a st h e
sum of the weight associated from node v to its neigh-
bors u in adjacency matrix A, their formal definitions
are in Equations (5) and (6), respectively. The transition
matrix M for RW is computed using the adjacency
matrix A and ws(v) and the transition probability Muv
from node v to node u is defined in Equation (7) where
w(v,u) is calculated by Equation (1)
adj(v)=
 
u|(v,u) ∈ E
 
(5)
ws(v)=
 
u∈adj(v)
w(v,u) (6)
Mvu = probability(v − u)
= w(v,u)/ws(v)
(7)
Let P0 be the initial probability vector constructed in
such a way that equal probabilities were assigned to all
the source nodes with sum of their probabilities equal
to 1. Let Ps be a vector in which a node in the network
holds the probability of finding itself in the random
walk process up to the step s, the probability of Ps+1 can
be derived by
Ps+1 = MTPs (8)
We plunge the transition matrix M and initial prob-
ability vector P0 into the iterative Equation (8). After
certain steps, the probabilities will reach a steady state
which is obtained by performing the iteration until the
difference between Ps and Ps+1 measured by L1 norm
falls below a very small number such as 10
-8.W ed e f i n e
the vector Preference(d) as the reference probability vector
represents a steady state probability vector of nodes for
the treatment merely by the drug target d.
Discovering potential co-target
A combination of primary drug target and co-target
should disrupt network and reduce the emergence of
drug resistance thus allowing the main drug to kill the
bacteria. The potentially predict co-target by looking at
the topological properties of nodes in a drug-treated
network in which a co-targeted protein is deleted or
inhibited corresponding to remove or hard to reach it
[27,28]. It is possible to analyze the consequences on
network structure by looking to the variations of the
probability of all the other nodes while inhibiting the
co-target protein. Given the weighted network of the
primary drug treated network, we modify the transition
matrix in order to determinate the probabilities of the
resulting interactions after deleting or inhibiting the
candidate co-targets. It is reasonable to assume the fol-
lowing constraints to specify the new transition matrix
M’:
(1) To inhibit proteins that are co-targets, the prob-
ability of the co-target nodes in the transition matrix
should be set to a small value ε. In order to represent
the inhibition of node in the network, the transition
probability from node to the co-target protein should
smaller than previous values. Therefore, we set the
range of the parameter ε from 0 to TPmin which is the
minimum probability of the edge in the original transi-
tion matrix M.
(2) The sum of the probability of the nodes should be
equal to 1, so the probabilities of the rest of nodes must
be re-adjusted accordingly if at least one of the edges is
set to ε.
In order to satisfy the above constraints, let ct(v)b ea
set of proteins whose nodes belong to adj(v) which are
also co-targets, we have the definition in Equation (9). If
ct(v) is an empty set, it denotes that node v does not
direct interact with any co-target that we set in the
experiment.
ct(v)=
 
u|adj(v) ∧ u is a co - target
 
(9)
For every node v in the network, if a node u in adj(v)
belongs to ct(v), we reset the probability of walking into
a co-target node with a small value ε (since it is
assumed to be inhibited), else, let the number of the
nodes in ct(v)a s| c t ( v) |a n dt h es u mo ft h ew e i g h t so f
the nodes in adj(v) which are not in ct(v)a sw s ’(v)
defined in Equation (10), we adjust the weight to each
node which is not in ct(v) based on the weight ratio of
w(v, u)a n dw s ’(v) and one minus the probabilities
attributed to co-target nodes as in Equation (11).
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w∈adj(v)−ct(v)
w(v,u) (10)
M 
vu = probaility(v → u)
=
⎧
⎨
⎩
ε u ∈ ct(v)
w(v,u)
ws (v)
 
1 −
   ct(v)
   ε
 
u / ∈ ct(v)
(11)
The small undirected network is represented in Figure
3 ( A )w h e r en o d eAi sap r i m a r yd r u gt a r g e ta n da l lt h e
weights of the edges are equal to one. Figure 3(B) is the
adjacent matrix A and entries of the original transition
matrix M are calculated according to Equation (7).
While we choose the node C to be a co-target, the mod-
ified transition matrix M’ is calculated according to
Equations (9)-(11). Take node B as an example, first we
get adj(B) = {A, C, E} and ct(B)={C} from Equation (9)
and then we set the probability of M’BC and M’DC to be
ε based on Equation (11). The probability of M’BA is cal-
culated by
M 
BA = probaility(B → A)
=
 
1 
3
1 
3 + 1 
3
 
 
1 − (1)ε
 
=
1
2
(1 − ε)
(12)
The probabilities of M’BE,M ’DE, and M’DF are set in a
similar manner. The initial probability P0 is formed such
that equal probabilities are assigned to the nodes that
are targeted by the drug and its co-target with the sum
equal to 1. In Figure 3(C) example, the initial probabil-
ities for the pair of the primary drug target and its co-
target are both set as 0.5 respectively. After certain
steps, the probability will reach a steady state to the
probability Pcotarget(d, t) under the treatment of the pri-
mary antibiotic target d and its co-target t. Finally, we
obtain a function F(d, t) which is shown in Equation
(13) for every primary drug target and co-target pair.
The function F(d, t) denotes the relative visit frequency
o ft h eg e n es e tG DR for the co-target Pcotarget(d, t)
against the reference probability Preference(d).T h el a r g e r
value of the F(d, t) d e n o t e st h a tt h i sc o - t a r g e th a sa
Figure 3 An example of the transition matrix in the co-target assignment.
Chen et al. BMC Systems Biology 2012, 6:5
http://www.biomedcentral.com/1752-0509/6/5
Page 6 of 14stronger influence to the active resistance gene set GDR
with respect to the reference probability where only the
drug target is under treatment.
F(d,t) =
 
g∈GDR
Pcotarget(d,t)g/Preference(d)g (13)
where Pcotarget(d, t)g denotes the probability of the g
th
gene which has the drug resistance in the vector Pcotarget
(d, t). After we calculate each gene t in active network
using Equation (11), we rank gene sorted by the value of
F(d, t) and try to identify potential co-targets that tend
to have larger impact to GDR.
Results and Discussion
Our interactome networks of Mtb H37Rv extracted from
STRING database which contains 3764 proteins with
179920 undirected interactions among them. We extract
microarray data from Gene Expression Omnibus (GEO)
at NCBI with accession number GSE1642 [29] which
contains the most frequently used drugs for the treat-
ment of Mtb, Isoniazid (INH) and Ethionamide (ETA).
INH is a first-line drug used worldwide to treat Mtb and
ETA is a second line drug. In the experiments, H37Rv
treated with 0.2 mg/mL and 0.4 mg/mL INH (in 1 μL/
mL EtOH) for 6 h with MIC (0.02 μg/mL) and control
cells treated with equivalent amount of EtOH for 6 h.
H37Rv also treated with 12 μg/mL and 40 μg/mL ETA
with MIC (0.5 μg/mL). It must be noted that it is possible
that the high concentration may lead to abnormal
expression but there may be also a higher probability to
develop drug resistance [2]. INH is known to be an inhi-
bitor of mycolic acid biosynthesis (MAP) and ETA is a
structural analog of INH that is also thought to inhibit
the same biosynthesis. The MAP model contains 219
reactions and 197 metabolites, mediated through 28 pro-
teins based on the complete and accurate with annota-
tions from the latest literature [30]. After mapping to the
microarray data, we use 21 proteins as source nodes for
A* search to extract active networks.
Gene expression analysis in treated Mtb: Isoniazid and
Ethionamide
Previous studies [31,32] discovered 71 genes relevant to
resistance mechanisms were classified into four types (a)
efflux pumps which transport drugs out of the cell, (b)
cytochromes and other target-modifying enzymes that
cause potential chemical modification of drug molecules,
(c) SOS-response and related genes leading to mutations
or its regulatory region, (d) proteins involved in hori-
zontal gene transfer (HGT) to import a target modifying
protein from its environment. The efflux pump proteins
directly pump the drug molecules out of the site of the
cell [33,34]. The cytochromes in the resistome are
known to modify the drug structure. The proteins clas-
sified under the SOS category are believed to be impor-
tant in mediating mechanisms important for DNA
repair and hence in the emergence of mutations that
give rise to drug resistance [35]. The proteins in the last
category give rise to capabilities of reducing the physio-
logical burden of the drug, typically by degrading the
drug in a suitable manner [36-38].
The variation of the gene expression in the microarray
data have shown that the lists of genes in fact were either
increased or decreased upon exposure to the drug [3].
Table 1 shows the number of the up and down regulated
genes belongs to curated resistance proteins microarray
data [19]. There are 1920 up-regulated genes, 1806
down-regulated genes and the expression values of the
38 genes are equal to zero in INH samples. On the other
hand, 1946 up-regulated genes, 1777 down-regulated
genes and the expression values of the 41 genes are equal
to zero in ETA samples. In the antibiotic efflux pumps
category, there are 7 and 8 up-regulated genes while 10
and 9 genes are in the down-regulated set in INH and
ETA samples. In SOS processes category, 5 up-regulated
and 4 down-regulated genes are in INH samples while
only 1 up-regulated gene and 8-down regulated genes in
ETA samples. We take the absolute value of expression
value to capture inhibitory activity (negative correlation)
as well as activation activity (positive correlation) and we
find that 31% (22/71) and 32.4% (23/71) of the genes’
absolute expression values are larger than the average of
the absolute expression values of all the genes in INH
and ETA samples. Two genes with expression values
which are larger than two standard deviations are iniA
and efpA in both INH and ETA data.
The drug response and resistance networks under
antibiotic treatment
We extract the paths with the length from three to
seven where seven is the maximum length of the all pair
Table 1 The number of the up and down regulated genes
that belong to the curated resistance proteins in INH and
ETA
Drug resistance INH ETA
Up
(+)
Down
(-)
Up
(+)
Down
(-)
Antibiotic efflux pumps 7 10 8 9
Hypothetical efflux pumps 2 2 1 3
Antibiotic degrading enzymes 1 0 1 0
Target-modifying enzymes 1 0 1 0
SOS and related genes 5 4 1 8
Genes implicated in horizontal gene
transfer (HGT)
1212
Cytochromes 15 20 20 15
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sity function of the score of the active networks and
there be parameters that can maximize the likelihood
function to fit the density function. A simple and rapid
method to calculate an approximate confidence interval
is based on the application of the central limit theorem.
We use the mean and variance to calculate the top 5%
area as lower limits of the 95
th percentile confidence
interval in the distribution. We extract 681 and 679
active genes involved in the active networks from INH
and ETA samples, respectively. Then, we identify the
potential drug resistance pathways under drug treatment
where at least one of curated resistance proteins is in
the paths and assemble them to the active networks.
There are 53 and 235 genes in GDR in INH and ETA
active resistance networks. The paths to different func-
tional resistance mechanisms for different drugs sug-
gested that a given target may have a higher propensity
for eliciting a specific mechanism of resistance [18].
From the functional enrichment point of view, we apply
the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) Gene Functional Classifica-
tion Tool http://david.abcc.ncifcrf.gov/ to find the
annotation for active gene set [39]. DAVID can con-
dense a list of genes or associated biological terms into
organized classes of related genes or biological modules
by using a novel agglomeration algorithm. This organi-
zation is accomplished by mining the complex biological
co-occurrences found in multiple sources of functional
annotation. We focus on the functional processes and
pathway enrichment of the active networks and select 3
out of 14 annotation categories related to the functional
pathways and processes including Biological Process and
Molecular Function in Gene Ontology (GO) and KEGG
pathways. We filter the results that have at least 3 genes
in each functional category with P-value < 0.05 and FDR
< 0.25 see Additional file 1. Both of the genes treated by
INH and ETA would facilitate the survival is seen
through fatty acid metabolic and synthase activity and
microarray experiments also show up-regulation of the
genes involved in these pathways to a great extent [40].
Biotin-requiring enzymes including acetyl-CoA carboxy-
lase, methylcrotonyl-CoA carboxylase, propionyl-CoA
carboxylase, and pyruvate carboxylase play essential
roles in cell metabolism for the survival and pathogen-
esis of Mtb [41]. The co-factors facilitate the transfer of
CO2 during carboxylation, decarboxylation, and trans-
carboxylation reactions in fatty acid and carbohydrate
metabolism. Glycerophospholipid metabolism and ethyl-
benzene degradation decreasing their gene expression
profiles indicate down-regulation in the mechanism of
the ETA drug resistance.
We find that fatty acid metabolism activity and mem-
brane metabolism are closely related to the cell wall
biosynthesis in both INH and ETA active networks. Mtb
has a very complex cell wall which is composed of the
cross-linked peptidoglycans linked to arabinogalactans,
and mycolic acids [42]. Lipoarabinomannan is presented
in the outer layer of the cell envelope which is anchored
in the cell membrane [43]. In addition, mycolic acids
have a distinctive chemical nature and a lack of mycolic
acid synthesis eventually results in loss of cellular integ-
rity and the bacteria death [44]. Therefore, we focus on
those processes and cell wall to explain the drug
response and resistance mechanism in Figure 4. Nodes
are labeled by their gene symbols and nodes in white
color denote the overlapping genes in both INH and
ETA active networks. Nodes in black color only exist in
INH active network and nodes in gray color only in
ETA active network. The dash arrow denotes the differ-
ent gene expression values in ETA samples.
The effect of INH is captured by modifying the interac-
tion of its known target, NADH-dependent enoyl-[acyl-
carrier-protein] reductase, inhA (Rv1484) [45]. Fatty acid
degradation pathway is activated for the degradation of
cell-membrane lipids due to the interruption of their bio-
synthesis by the inactivation of drug target inhA [45]. We
reveal that the mechanism of INH is known to inhibit
the biosynthesis of mycolic acid to break the cell wall by
disrupting the fatty acid synthesis-II (FAS-II) pathways in
Figure 4. The up-regulated FAS-II pathway is closely
connected to a similar up-regulated fatty acid degrada-
tion pathway assembled by the enoyl-hydratases and
acyl-CoA ligases as well as by the putative acyl-CoA
dehydrogenase [45]. Gene inhA formed a complex
between the kasA-acpM proteins was proposed to be the
primary targets in both INH and ETA samples. The kasA
genomic consists of five genes in an operon (fabD, acpM,
kasA, kasB and accD6) and all of them encode for
enzymes that are involved in the fatty acid biosynthesis
pathway [46-49]. The NADH dehydrogenase (ndh) gene
is bound to the active site of inhA and we also discover
that emb proteins (embA, embB, embC) encoded a func-
tional arabinosyltransferase are also involved in the bio-
genesis of the mycobacterial cell wall. They may play
important roles in the cellular homeostasis of the cell
and the expressions of these genes activate certain path-
ways which could link to the resistance. Although ETA
and INH are similar to work against the drug treatment,
we find that ETA as a thioamide drug which has been
shown to be metabolized by a specific fad enzyme,
Rv3854c (ethA) and different routes to the FAS-II path-
way. The major DNA polymerase dnaE2 participates in
DNA repair synthesis and SOS-related genes which is
up-regulated in INH active network while it is down-
regulated in ETA active network. On the other hand, we
assume that Mtb treated with INH has stronger relation-
ship with the SOS process to trigger drug resistance.
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Page 8 of 14Except the global view of the processed in drug
response and resistance mechanism, we list the paths
with small scores which belong to different functional
resistance mechanisms in Tables 2 and 3 where the aver-
age value Savg(P) denotes the overall score(p) divided by
the number of genes involved in the path p.W eo b s e r v e
that the multidrug efflux pumps appear to be one of the
major resistance mechanisms in both INH and ETA
resistance network. We show that the linear paths with
small scores where fadE family are negatively controlled
genes that binds to the transcription factors for regulat-
ing the expression of fatty acid biosynthesis [46]. Drug
resistance related genes efpA, ccsA, cysG and dnaE2 are
strongly associated with fadE family which can contribute
directly to the emergence of drug resistance. We observe
that efpA exists in both active networks and previous
experimental observations from a time-kill kinetics study
of Mtb showed that the efflux pumps are the predomi-
nant mechanism of drug resistance for INH and ETA
[49,50]. The expression of the drug transporting genes
(efpA, iniA, iniB, cysG, and ccsA) cause pumping out of
the active drug from the cell where cysG and ccsA cata-
lyze the NADPH-dependent processes strongly signifi-
cant in INH active network. Our findings suggest
consistency with the recent experimental results and
numbers of the proteins refer to the mechanism of the
resistance are identified from literature see Additional
file 2. We suggest that different drug targets cause differ-
ent mechanism of the drug resistance and hence different
drugs could trigger resistance through different routes.
The variations of F(d, t) while setting different values of
the parameter epsilon
In the experiments, TPmin in INH and ETA samples are
both 0.0025. We run our method using the values of the
parameter ε between 0 and 0.0025 with step 0.0005 and
get the set of the probabilities of the nodes calculated
by Equation (13). Then, we show the absolute value of
Cell membrane
FAS II
elongation Cycle 
fabD ↑ accD6 ↑
fas ↑ plsB ↓
kasA-acpM ↑
fbpC↑ 
fbpB↓ 
ccsA ↑ 
kasB↑  ruvA↑ 
iniA ↑ + iniB↑ 
efpA↑ 
ndh↑ 
katG↓ 
H2O2 by product
ahpC↑  inhA ↓
FAS I Cycle 
fabH ↑
fadE23 ↑
pks13 ↑
Mature mycolates
Terminal step in mycolic acid maturation
Mycolic acid cell wall
cysG↑ 
ethA↑ 
embA↓  embB↓ 
Exists in INH
Exists in ETA
dnaE2
INH Expression 
ETA Expression 
Figure 4 Part of the active networks treated with INH and ETA.
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Page 9 of 14the variation of probability of each gene among different
values of the parameter ε in INH and ETA samples in
Figure 5. The results in both INH and ETA samples
have small mean and standard deviation and also denote
that the range of the parameter ε we set does not affect
the probability of each gene.
The potential co-targets discovered by random walk
model
The unusual multimethyl-branched fatty acids in Mtb
are important for the resistance processes of antibiotic
resistance, pathogen survival, and virulence [51-53].
Therefore, inhibitors aimed at those processes have high
potential to become new anti-tuberculosis therapeutics
[54]. We recently suggest the concept of primary drug
target and co-target pairs where the co-target could be a
key protein in mediating drug resistance. We apply our
method to find the potential co-targets with the larger
values of the F(d, t) in Equation (13). Upon analysis of
the potential co-targets only be the up-regulated genes,
this indicates that the up-regulated genes seem to have
Table 2 Top paths of INH resistance in active sub-
networks
Top paths in active sub-networks Savg(P)
Antibiotic efflux pumps
kasB–fabD–kasA–efpA–fbpC2–fbpB–ccsA 1.277
kasB–kasA–fadE24–efpA–fbpC2–fbpB–ccsA 1.327
kasB–kasA–efpA–fadE24–echA18’–fbpB–ccsA 1.348
Antibiotic degrading enzymes
fabG1–kasB–acpM–kasA–sigC–blaC 1.247
fabD–kasB–kasA–sigC–blaC 1.299
accD4–accD6–kasB–kasA–sigC–blaC 1.331
fabG1–acpM–accA3–fabD–kasA–sigC–blaC 1.345
SOS response
kasB–kasA–accD6–fadE23–fadE24–echA18’–dnaE2 1.255
accA3–fabD–kasB–kasA–acpM–ruvA–ahpC 1.262
kasB–acpM–accD6–fadE23–fadE24–echA18’–dnaE2 1.284
inhA–kasB–fabD–kasA–acpM–ruvA–ahpC 1.304
inhA–kasA–kasB–accD6–fadE23–echA18’–dnaE2 1.333
fabD–kasB–accD6–fadA2–fadE24–echA18’–dnaE2 1.337
Cytochromes
inhA–kasB–kasA–acpM–gpdA1–fbpB–ccsA 0.961
kasA–kasB–accD6–fadE23–fadD11–fbpB–ccsA 0.964
kasA–kasB–accD6–fadE23–echA7–fbpB–ccsA 0.975
kasA–kasB–accD6–fadE23–echA5–fbpB–ccsA 0.998
kas–acpM–kasB–fabD–atpD–ctaD–aceE 1.214
kasB–acpM–kasA–fabD–ctaD–aceE 1.247
kasA–kasB–acpM–accA3–fabD–ctaD–aceE 1.248
Table 3 Top paths of ETA resistance in active sub-
networks
Top paths in active sub-networks Savg(P)
Antibiotic efflux pumps
birA–accA3–fabD–kasA–Rv0342–Rv0341–chaA 1.268
birA–kasB–accD6–fadE23–fadE24–efpA–Rv3570c 1.273
birA–fabD–kasB–acpM–kasA–efpA–Rv3570c 1.359
birA–kasB–fabD–acpM–kasA–Rv0342–Rv0093c 1.364
birA–kasA–kasB–Rv2248–Rv0342–Rv0341–chaA 1.367
Target-modifying enzymes
fabD–kasB–kasA–acpM–Rv1988–Rv1987–Rv1875 1.402
Figure 5 The absolute values of the variations of F(d, t) among
different values of the parameter epsilon in INH and ETA
samplesTables.
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specific purpose. We display 10 and 15 potential co-tar-
gets at the top 3% of the function F(d, t) in Table 4 and
5, respectively.
Gene radA, Rv2165c, fadA, pgk, Rv3802c, and atpB
are all annotated as potential targets in a comprehensive
target identification pipeline including a network analy-
sis of the protein-protein interactome, a flux balance
analysis of the reactome, experimentally derived pheno-
type essentiality data, antibiotic resistance, sequence
analyses and a structural assessment of targetability [55].
Large numbers of the enzymes responsible for fatty acid
metabolism are also profiled in both cell wall and mem-
brane fractions and our results observe several potential
co-targets belong to FadEs, acyl-CoA and enoyl-CoA
which are related processes on the fatty acid breakdown
in Table 4[56,57]. One of the fadEs, fadE14 has shown
the distinct homology to proteins involved in lipid meta-
bolism [58]. Previous studies have shown that acetyl
coenzyme A (acetyl-CoA) carboxylase is a key bacterial
component in ATPase enzymatic activity and essential
protein-protein interaction which catalyzes the first step
in fatty acid synthesis and cell growth [59]. One of the
AccD5 (5th subunit of acyl-CoA carboxylases (ACCase),
has been strongly implicated as one of the essential
ACCases important for cell envelope lipid biosynthesis
and also identified as inhibitor [60]. The other acetyl-
CoA carboxylase-related proteins involved in the bio-
synthesis of unique cell wall lipids may be explored as
possible targets for new drug targets. The conserved
secretion (Sec) pathways perform the protein export
which is essential participating in inserting integral
membrane proteins into the cytoplasmic membrane for
virulence with the help of the signal recognition particle
(SRP) [61,62]. We show that potential co-target Ffh is a
SRP subunit which is associated with adenosine tripho-
sphate (ATP) binding cassette transporter type of pro-
teins are known to be involved in the efflux of drugs in
bacterial systems [63]. DnaE2 polymerase response is
up-regulated in INH active network and it is strongly
associated with error-prone DNA repair such as radA.
SOS response is significant up-regulated in INH samples
therefore our method suggest that inhibition of the
DNA repair genes may reduce the survival of the bac-
teria. Although Rv2137c is a hypothetical protein, it
strongly interacts with the plasma membrane proteins
lipoproteins, adrenodoxin oxidoreductase and cell wall
processes which is annotated in STRING database [20].
The potential co-target cysG in INH active network is
strongly related to the efflux pump processes and efflux
inhibitor is also annotated in potential targets to combat
antibiotic resistance [64].
In Table 5, we discover Rv1343c (lprD) which was
previously shown to be cell wall-associated by proteo-
mics and it could be a specific inhibitor to counter ETA
resistance [65]. Lipoproteins such like lprD carry out
important functions efficiently at the membrane aqu-
eous interface and its biosynthetic pathway is also essen-
tial for bacterial viability [66]. Bacteria may be inherently
resistant with a particular type of cell wall structure with
an outer membrane that establishes a permeability bar-
rier against the antibiotic. Previous works denoted that
FadA5 appears more times in the shortest paths and
also considered it as a hub in the resistance pathways
[2]. ATP hydrolysis inhibitor such as atpB would inhibit
the generation of cellular energy and it would play a
role in the bacteria’s defence against cell damage.
TMC207 (formerly known as R207910) specifically inhi-
bits Mtb by inhibition of ATP synthesis was recently
reported to have a potent and selective anti-mycobacter-
ial activity in Phase II clinical trials as a second-line TB
drug [67]. Our identification of mycobacterial acid phos-
phatase may a new target preventing the establishment
of intracellular in Mtb and this finding is also character-
ized in previous papers [68]. Boshoff et al. studies
demonstrated that the genes in the NAD biosynthetic
pathway offers an important view to understand of a
resistance mechanism and also can be an attractive
potential targets [69].
The essential genes are required to sustain cellular life
and they make excellent to be drug targets. In Table 4
and 5, there are ~30% of genes in the co-targets set are
essential based on the essentiality information retrieved
from TB [70] and DEG v5.0 database [71]. It is notice-
able that those essential genes in the co-target sets have
fundamental roles in cell and inhibition of each of them
is harmful for cell survival. On the other hand, the
selected co-targets have good properties in biological
and graph theory aspects. The biological validation for
Table 4 Top 10 co-targets for countering drug resistance
under INH treatment
Co-
target
Exp Essential Annotation Ref
radA 0.30 Not Essential DNA repair protein [55]
fadE10 0.19 Not Essential acyl-CoA dehydrogenase [56,57]
Rv2165c 1.05 In Vitro
essential
conserved hypothetical
protein
[55]
echA17 0.25 Not Essential enoyl-CoA hydratase
Rv2137c 1.32 Not Essential conserved hypothetical
protein
Ffh 0.25 In Vitro
essential
signal recognition particle
protein
[61-63]
fadE14 0.12 Not Essential acyl-CoA dehydrogenase [58]
fadA 0.20 Not Essential acyl-CoA thiolase [55]
fadE12 0.15 Not Essential acyl-CoA dehydrogenase [56,57]
cysG 0.16 In Vitro
essential
multifunctional siroheme
synthase
[64]
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it turns out that some of our predicted results had been
reported in the public literature for validation. Accord-
ing to our results, we focus on the strategies adapted by
M t bt oc o u n t e rt h ed r u gr e s i s t a n c eb ya s s e s s i n g
mechanical barrier and ATP energy. Mechanical barrier
is one of the protective strategies employed by Mtb
against drug resistance by the alteration of the lipogly-
cans or fatty acid processes. ATP energy-based and cell
wall-related inhibitors may make bacteria loss energy to
survive against cell damage.
Conclusions
To tackle the problem from a drug resistance perspec-
tive, it is essential to understand the molecular mechan-
isms by which bacteria acquire drug resistance using a
network-based approach. We develop a computational
workflow for giving new insights to bacterial drug resis-
tance which can be gained by a systems-level analysis of
bacterial resistance networks. In our approach, we utilize
i n f o r m a t i o no nS T R I N Gd a t abase and expression data
to construct a weighted network and to decipher the
active networks related to drug resistance using A*
search method. We discover that genes in both INH
and ETA active networks would facilitate survival
related to trigger the processes in cell wall, fatty acid
metabolism and synthesis, and NADH-related processes.
Efflux pumps appear to be the major mechanisms of
resistance under INH and ETA drug treatment in Mtb
and SOS response is significant involved in INH active
network. Several correlations for the predicted resistance
paths corresponding to the experimental data are avail-
able in literature suggesting that information flows
through the identified routes are probable and biologi-
cally significant.
We globally identify the potential co-targets which
have higher probabilities to affect the genes related to
the drug resistance mechanism through the main and
back-up paths using our random walk model. Those co-
targets related to lipo-rich membrane, ATP energy and
cell wall-related processes f o rc o u n t e r i n gd r u gr e s i s -
tance. Knowledge of the active networks under drug
treatment help us address more systematic and novel
ways to discover the potential co-targets with good
properties in biological and graph theory aspects for
overcoming the problem of drug resistance. It is impor-
tant to bear in mind that studies on a theoretically
derived network may have some limitations due to miss-
ing out some important interactions have not been iden-
tified. In the future, the genome of the drug-resistant
strain and non-drug-resistant strain can be compared to
identify genes which also worth considering as signifi-
cant feature for co-targets in the sequence level. Inhibi-
tion of the primary target and the co-target
simultaneously seems to be a feasible and novel way to
overcome the problem of drug resistance for other
diseases.
Additional material
Additional file 1: The functional enrichment analysis of the genes
treated by INH and ETA using David toolkit with p-value < 0.05 and
FDR < 0.25. File name: additionalfile_1.pdf. We do the functional
enrichment analysis of the genes in the drug resistance network treated
by INH and ETA using DAVID toolkit. The first column denotes the
functional terms. The second and third columns denote the p-value and
FDR values. The last column “Cum(exp)” gives the cumulative expression
value of the genes annotated in the functional term.
Additional file 2: Known genes related to the drug response and
resistance under INH and ETA treatment. File name: additionalfile_2.
pdf. We list the drug response and resistance genes which have received
considerable attentions from public literature.
Table 5 Top 15 co-targets for countering drug resistance under ETA treatment
Co-target Exp Essential Annotation Ref
pgk 0.12 In Vitro essential phosphoglycerate kinase [55]
Rv3802c 0.25 In Vitro essential conserved membrane protein [55]
Rv1343c 0.37 Not Essential lipoprotein [65,66]
Rv1474c 0.03 Not Essential transcriptional regulator
Rv0481c 0.08 Not Essential hypothetical protein
Rv2455c 0.63 Not Essential oxidoreductase alpha subunit
accA2 0.36 In Vitro essential acetyl-/propionyl-CoA carboxylase alpha subunit [59]
fadD18 0.05 Not Essential fatty-acid-CoA ligase
fadA5 0.45 Not Essential acetyl-CoA acetyltransferase [2]
atpB 0.46 In Vitro essential ATP synthase A chain [55,67]
Rv2367c 0.28 Not Essential hypothetical protein
Rv3355c 0.01 Not Essential conserved hypothetical protein
Rv2199c 0.55 Not Essential conserved membrane protein
Rv3310 1.38 Not Essential acid phosphatase [68]
nadC 0.59 Not Essential nicotinate-nucleotide pyrophosphatase [69]
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